Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Search ...
VBCN - July 2014 Volume 1, No 2
Neurologists Must Maintain Patient-Centered Care Even When Facing Economic Pressures
By
Wayne Kuznar
Health Economics
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Neurologists are amidst a social transformation that threatens their professionalism, their ethical foundation, and their patients, said James L. Bernat, MD, Professor of Neurology and of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Read More
Rapid CD4 Cell Recovery with Alemtuzumab Treatment Not a Biomarker for MS Activity
By
Rosemary Frei, MSc
Multiple Sclerosis
VBCN - July 2014 Volume 1, No 2
Results of a new study suggest that the rate of peripheral CD4 replenishment after the administration of alemtuzumab, a lymphocyte-depleting anti-CD52 monoclonal antibody, does not correlate with multiple sclerosis (MS) activity in patients with relapsing-remitting MS.
Read More
Could Immunotherapy Be the Future of Alzheimer’s Therapy?
By
Mark Knight
Alzheimer’s Disease/Dementia
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Immunization against amyloid-beta and tau protein, starting in the preclinical period, may represent the future in the treatment of Alzheimer’s disease (AD), said David M. Holtzman, MD, Chairman of Neurology, Washington University, St Louis, MO, during the presidential plenary session at the 2014 American Academy of Neurology meeting.
Read More
Fourfold Variability Found in Hospital Charges for Stroke Diagnostic Tests
By
Wayne Kuznar
Stroke
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Some of the most expensive diagnostic tests for stroke or transient ischemic attack (TIA) do not affect patient management but expose patients to potential harm, said Pratik D. Bhattacharya, MD, MPH, Assistant Professor of Neurology, Wayne State University, Detroit, MI.
Read More
Earlier Use of Adjunctive Antiepileptic Drugs in Patients with Refractory Disease Could Reduce Costs
By
Wayne Kuznar
Health Economics
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Changing from monotherapy to the early initiation of adjunctive therapy with a second antiepileptic drug in patients with partial-onset seizures may lead to a substantial reduction in healthcare utilization and costs, according to a retrospective claims database analysis presented in a poster at the 2014 American Academy of Neurology meeting.
Read More
Is No Evidence of Disease Activity an Achievable Goal in Patients with RRMS?
By
Wayne Kuznar
Multiple Sclerosis
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Achieving no evidence of disease activity (NEDA) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) is a clinically meaningful goal, but a strategy to achieve it remains untested, said Robert Bermel, MD, a neurologist at the Mellen Center for Multiple Sclerosis, the Cleveland Clinic, at the 2014 American Academy of Neurology meeting.
Read More
Medical Marijuana Helpful for Some MS Symptoms
By
Wayne Kuznar
Multiple Sclerosis
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—A systematic literature review conducted by the American Academy of Neurology (AAN) shows that certain forms of medical marijuana can be useful to treat some symptoms of multiple sclerosis (MS), but the evidence is insufficient to support its use in other neurologic diseases, and there are a number of safety concerns with medical marijuana.
Read More
Extended Natalizumab Dosing May Reduce PML Risk in Patients with Multiple Sclerosis
By
Wayne Kuznar
Multiple Sclerosis
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Extending the dosing interval of natalizumab to every 6 to 8 weeks may lower the risk for progressive multifocal leukoencephalopathy (PML) without affecting efficacy in patients with multiple sclerosis (MS).
Read More
Estriol Added to Glatiramer Acetate Improves Cognition, Reduces Relapse Rate in MS
By
Mark Knight
Multiple Sclerosis
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Estriol may represent a future novel treatment option for patients with relapsing-remitting multiple sclerosis (RRMS). In a phase 2 randomized, double-blind, placebo-controlled trial of women with RRMS, estriol, given with glatiramer acetate, reduced the relapse rate by almost 50% with only 1 year of treatment and improved cognition, reported Rhonda Voskuhl, MD, Director of the MS program, University of California, Los Angeles, at the 2014 meeting of the American Academy of Neurology.
Read More
Knowledge of Antiepileptic Drug Formulations Key to Accurate Prescribing
By
Wayne Kuznar
Epilepsy
VBCN - July 2014 Volume 1, No 2
Philadelphia, PA—Multiple formulations and generic equivalents of antiepileptic drugs are prevalent, and choosing between them can help optimize seizure control and minimize adverse effects, said Carl W. Bazil, MD, PhD, Director, Comprehensive Epilepsy Center, Columbia University Medical Center, New York, at the 2014 American Academy of Neurology (AAN) meeting.
Read More
Page 1 of 3
1
2
3
Search ...
Home
Issues
Latest Issue
Issue Archive
Special Issues
Categories
Subscribe to
Value-Based Care in Neurology
Stay up to date with personalized medicine by subscribing to recieve the free
VBCN
e‑Newsletter.
I'd like to recieve:
VBCN
e‑Newsletter
I have reviewed and consent to the terms of
VBCN
's
Privacy Policy
, and
VBCN
has my permission to retain my information in its database, and to forward pertinent communications to me.